Santhera to Present Result of DELOS & SYROS Study at the 2019 MDA Clinical and Scientific Conference 

 Santhera to Present Result of DELOS & SYROS Study at the 2019 MDA Clinical and Scientific Conference  

Santhera Reports Submission of Marketing Authorization Application to the EMA for Puldysa (Idebenone) in Duchenne Muscular Dystrophy

Shots:

  • The P-III DELOS study involves assessing of Idebenone (900 mg/day) vs PBO in 64 patients with Duchenne muscular dystrophy (DMD) for 52wks. & P-II DELPHI study with 2-year extension study (DELPHI-E). SYROS study involves assessing of Idebenone (900 mg/day) in 18 patients under Expanded Access Programs (EAPs) who completed the DELOS study
  • The P-III Delos study resulted in meeting 1EP as slow loss of respiratory function. The Syros study resulted in long-term & consistent long-term reduction in rate of respiratory function & maintained up-to 6yrs.
  • Idebenone is a synthetic benzoquinone & a cofactor for the enzyme NAD(P)H: quinone oxidoreductase (NQO1) capable of stimulating mitochondrial electron transport, reducing and scavenging reactive oxygen species (ROS) and supplementing cellular energy levels

Click here to read full press release/ article | Ref: Santhera | Image: Twitter

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post